GHRS
GH Research PLC NASDAQ Listed Jun 25, 2021$22.44
After hrs
$22.79
+1.56%
Mkt Cap $1.4B
52w Low $9.46
85.4% of range
52w High $24.66
50d MA $16.41
200d MA $14.67
P/E (TTM)
-26.2x
EV/EBITDA
-8.8x
P/B
4.5x
Debt/Equity
0.0x
ROE
—
P/FCF
-17.8x
RSI (14)
—
ATR (14)
—
Beta
1.00
50d MA
$16.41
200d MA
$14.67
Avg Volume
222.8K
About
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.29 | -0.23 | +20.7% | 15.17 | +0.6% | +5.0% | +5.3% | +3.9% | -0.3% | +2.3% | — |
| Nov 6, 2025 | AMC | -0.23 | -0.23 | +0.0% | 13.41 | -1.3% | +0.7% | +1.0% | +6.0% | +11.9% | +2.3% | — |
| Aug 7, 2025 | AMC | -0.22 | -0.15 | +31.8% | 12.10 | -0.3% | +2.6% | -2.5% | +0.3% | +3.8% | +5.6% | — |
| May 8, 2025 | AMC | -0.61 | -0.19 | +68.9% | 10.80 | +1.6% | -3.9% | -5.9% | -6.9% | -7.6% | -0.9% | — |
| Feb 27, 2025 | AMC | -0.23 | -0.17 | +26.1% | 10.65 | -2.4% | -4.9% | -13.5% | -11.8% | -2.3% | -0.9% | — |
| Nov 14, 2024 | AMC | -0.25 | -0.23 | +8.0% | 8.97 | +8.5% | +1.3% | +5.6% | +7.1% | +22.1% | +7.2% | — |
| Sep 3, 2024 | AMC | -0.23 | -0.20 | +13.0% | 9.81 | +1.6% | -13.7% | -13.7% | -16.1% | -13.4% | -18.3% | — |
| May 3, 2024 | AMC | -0.22 | -0.15 | +31.8% | 11.68 | +5.3% | +0.1% | +3.4% | +2.7% | +2.7% | +9.7% | — |
| Feb 29, 2024 | AMC | -0.20 | -0.21 | -5.0% | 8.88 | -0.1% | -4.3% | -8.4% | -4.3% | -4.7% | -7.9% | — |
| Nov 9, 2023 | AMC | -0.20 | -0.11 | +45.0% | 7.95 | -1.0% | +3.3% | -5.7% | -4.4% | -1.0% | -7.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.17 | $15.26 | +0.6% | +5.0% | +5.3% | +3.9% | -0.3% | +2.3% |
| Mar 6 | Needham | Maintains | Buy → Buy | — | $15.17 | $15.26 | +0.6% | +5.0% | +5.3% | +3.9% | -0.3% | +2.3% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.85 | $14.45 | -2.7% | +7.8% | +3.0% | +7.7% | +2.2% | +7.3% |
| Jan 23 | RBC Capital | Maintains | Outperform → Outperform | — | $16.74 | $16.90 | +1.0% | -0.1% | -0.8% | -3.2% | -4.1% | -3.0% |
| Jan 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.46 | $16.02 | +3.6% | -8.7% | +16.1% | +0.6% | -2.9% | -1.6% |
| Jan 6 | Needham | Maintains | Buy → Buy | — | $15.46 | $16.02 | +3.6% | -8.7% | +16.1% | +0.6% | -2.9% | -1.6% |
| Jan 5 | Needham | Maintains | Buy → Buy | — | $13.24 | $18.82 | +42.1% | +16.8% | +6.6% | +35.6% | +17.4% | +13.4% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.50 | $13.74 | +1.8% | +0.3% | +5.3% | +11.1% | +1.6% | +3.7% |
| Jun 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.68 | $11.76 | +0.7% | +7.4% | +1.8% | +6.2% | +6.5% | +4.4% |
| May 9 | Guggenheim | Maintains | Buy → Buy | — | $10.80 | $10.97 | +1.6% | -3.9% | -5.9% | -6.9% | -7.6% | -0.9% |
Data updated apr 25, 2026 11:22am
· Source: massive.com